About the Autoimmune Cell Therapy Summit 2026

Why Attend the 4th Cell Therapy for Autoimmune Disease Summit?

As autoimmune cell therapy transitions from breakthrough case studies to broad clinical validation, 2026 represents a pivotal year for the industry. At the 4th Cell Therapy for Autoimmune Disease Summit, join the only dedicated forum that brings together developers of CAR-T, NK, Treg, MSC, and in vivo cell therapies to discuss the latest clinical readouts, translational strategies, and commercialization considerations shaping the future of immune reset therapies.

With two focused content tracks on Preclinical Development & Translation and Clinical Development, dedicated networking opportunities, investor and pharma perspectives, and discussions spanning lupus, multiple sclerosis, type 1 diabetes, stiff person syndrome, and beyond, this summit provides a comprehensive view of where the field is headed next.

View the Agenda

What to Expect in 2026?

Analyze Transformative Clinical Readouts

Benchmark the latest CAR-T, NK, and Treg therapy data alongside leaders from Artiva Biotherapeutics and understand what these results mean for the future treatment paradigm.

Evaluate Next-Generation Autoimmune Cell Therapy Platforms

Discover how Kite Pharma is advancing novel engineering strategies designed to improve efficacy, durability, and safety across autoimmune indications.

Explore Scalable In Vivo Approaches

Hear from CPTx as the field looks beyond traditional manufacturing models and towards in vivo engineered cell therapies capable of serving larger patient populations.

Learn Global Clinical Development Strategies

Gain insights from Overland Therapeutics on accelerating development through innovative trial designs, regional partnerships, and emerging autoimmune opportunities.

Prepare for Commercial Adoption

Understand the challenges of bringing autoimmune cell therapies to broader patient populations with perspectives from Orca Bio on access, scalability, and long-term adoption.

Connect with the Next Wave of Industry Leaders

Network directly with pioneers, including PolTREG and other innovators, driving the transition from proof-of-concept studies to potentially curative therapies.

Divide & Conquer Across the Two Tracks

To maximize your team's takeaways and enhance cross-functional collaboration, the 2026 agenda is expertly curated across two tracks. We attracted representation from C-suite leaders to scientific and business development teams to fast-track your pipeline progression.

Preclinical & Translational Track

Benchmark novel antigen selection strategies, translational models, biomarker development, allogeneic innovations, in vivo engineering approaches, and next-generation platform technologies. Featuring speakers from Kite Pharma, CPTx, Cabaletta Bio, and Sail Biomedicines.

Clinical Track

Learn from developers generating clinical data across lupus, multiple sclerosis, stiff person syndrome, and other autoimmune indications. Join experts from Artiva Biotherapeutics, Mesoblast, PolTREG, Orca Bio, and Medical University of South Carolina as they discuss patient selection, durability of response, safety, CRS management, endpoint development, and regulatory considerations.